Given the recent development of selective ROCK2 inhibitors, such as KD02539, we next investigated whether the observed effects of ROCK2 on MYC protein stability in ABC-DLBCL could be pharmacologically targeted. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.